• Login
    View Item 
    •   Home
    • Colleges & Programs
    • Medical College of Georgia (MCG)
    • Department of Pharmacology and Toxicology
    • Department of Pharmacology and Toxicology: Faculty Research and Presentations
    • View Item
    •   Home
    • Colleges & Programs
    • Medical College of Georgia (MCG)
    • Department of Pharmacology and Toxicology
    • Department of Pharmacology and Toxicology: Faculty Research and Presentations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of Scholarly CommonsCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    About

    AboutCreative CommonsAugusta University LibrariesUSG Copyright Policy

    Statistics

    Display statistics

    Role of the central cholinergic system in the therapeutics of schizophrenia.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    CN-6-286.pdf
    Size:
    140.9Kb
    Format:
    PDF
    Download
    Authors
    Terry, Alvin V.
    Issue Date
    2009-06-09
    URI
    http://hdl.handle.net/10675.2/125
    
    Metadata
    Show full item record
    Abstract
    The therapeutic agents currently used to treat schizophrenia effectively improve psychotic symptoms; however, they are limited by adverse effects and poor efficacy when negative symptoms of the illness and cognitive dysfunction are considered. While optimal pharmacotherapy would directly target the neuropathology of schizophrenia neither the underlying neurobiological substrates of the behavioral symptoms nor the cognitive deficits have been clearly established. Abnormalities in the neurotransmitters dopamine, serotonin, glutamate, and GABA are commonly implicated in schizophrenia; however, it is not uncommon for alterations in the brain cholinergic system (e.g., choline acetyltransferase, nicotinic and muscarinic acetylcholine receptors) to also be reported. Further, there is now considerable evidence in the animal literature to suggest that both first and second generation antipsychotics (when administered chronically) can alter the levels of several cholinergic markers in the brain as well as impair memory-related task performance. Given the well-established importance of central cholinergic neurons to information processing and cognition, it is important that cholinergic function in schizophrenia be further elucidated and that the mechanisms of the chronic effects of antipsychotic drugs on this important neurotransmitter system be identified. A better understanding of these mechanisms would be expected to facilitate optimal treatment strategies for schizophrenia as well as the identification of novel therapeutic targets. In this review, the following topics are discussed: 1) the central cholinergic system in schizophrenia 2) effects of antipsychotic drugs on central cholinergic neurons 3) important neurotrophins in schizophrenia, especially those that support central cholinergic neurons; 4) novel strategies to optimize the therapeutics of schizophrenia via the use of cholinergic compounds as primary (i.e., antipsychotic) treatments as well as adjunctive, pro-cognitive agents.
    Citation
    Curr Neuropharmacol. 2008 Sep; 6(3):286-292
    ae974a485f413a2113503eed53cd6c53
    10.2174/157015908785777247
    Scopus Count
    Collections
    Department of Pharmacology and Toxicology: Faculty Research and Presentations

    entitlement

    Related articles

    • Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism.
    • Authors: Terry AV Jr, Mahadik SP
    • Issue date: 2007 Mar
    • Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.
    • Authors: Foster DJ, Jones CK, Conn PJ
    • Issue date: 2012 Dec
    • [Cholinergic hypothesis in psychosis following traumatic brain injury and cholinergic hypothesis in schizophrenia: a link?].
    • Authors: Bennouna M, Greene VB, Defranoux L
    • Issue date: 2007 Sep
    • α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future.
    • Authors: Terry AV Jr, Callahan PM
    • Issue date: 2020 Jun 15
    • On the trail of a cognitive enhancer for the treatment of schizophrenia.
    • Authors: Stip E, Chouinard S, Boulay LJ
    • Issue date: 2005 Feb
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.